| Zurich | |
| 0 | |
| Develops breakthrough synthetic nanoparticle-based vaccines and immunotherapeutic drugs for respiratory diseases and cancer. | |
| Virometix lead product is an epitope-optimized synthetic nanoparticle vaccine against Respiratory Syncytial Virus (RSV) currently in preclinical development. | |
| GHASPARIAN Arin | |
| www.virometix.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 9 fois.